Last reviewed 2026-05-27 · How we verify

Yupingfeng Powder granules

Prof. Lin Zhixiu · Phase 2 active Small molecule ✓ Verified May 2026

Yupingfeng Powder granules is a Small molecule drug developed by Prof. Lin Zhixiu. It is currently in Phase 2 development. Also known as: Yupingfeng Powder with variation.

Yupingfeng Powder granules are being studied as a potential treatment for Allergic Rhinitis in a randomized controlled trial. The exact mechanism of action of Yupingfeng Powder granules is currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Yupingfeng Powder granules
Also known as	Yupingfeng Powder with variation
Sponsor	Prof. Lin Zhixiu
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effects of Using Yupingfeng Powder with Variation for the Treatment of Allergic Rhinitis (PHASE2)
Study of Yupingfeng Powder Treating Allergic Rhinitis (AR) (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Yupingfeng Powder granules CI brief — competitive landscape report
Yupingfeng Powder granules updates RSS · CI watch RSS
Prof. Lin Zhixiu portfolio CI

Frequently asked questions about Yupingfeng Powder granules

What is Yupingfeng Powder granules?

Yupingfeng Powder granules is a Small molecule drug developed by Prof. Lin Zhixiu.

Who makes Yupingfeng Powder granules?

Yupingfeng Powder granules is developed by Prof. Lin Zhixiu (see full Prof. Lin Zhixiu pipeline at /company/prof-lin-zhixiu).

Is Yupingfeng Powder granules also known as anything else?

Yupingfeng Powder granules is also known as Yupingfeng Powder with variation.

What development phase is Yupingfeng Powder granules in?

Yupingfeng Powder granules is in Phase 2.

Manufacturer: Prof. Lin Zhixiu — full pipeline
Also known as: Yupingfeng Powder with variation

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing